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Abstract: (1) Background: Little is currently known about the health impacts of daily-life
moderate-to-vigorous physical activity (MVPA) in relation to the development of post-transplant
diabetes mellitus (PTDM) and the long-term survival of renal transplant recipients (RTRs). (2) Methods:
We analyzed self-reported data on MVPA within non-occupational and occupational domains,
estimated with the SQUASH questionnaire, from a prospective cohort study of RTRs (n = 650)
with a functioning graft exceeding 1 year. PTDM diagnoses were based on plasma glucose levels
(≥126 mg/dL), HbA1c (≥6.5%), and the use of antidiabetic medication. Mortality data were retrieved
from patient files up to the end of September 2015. (3) Results: During a median follow-up period
of 5.3 years, 50 patients (10%) developed PTDM and 129 (19.8%) died. Of these deaths, 53 (8.9%)
were caused by cardiovascular disease. Cox regression analyses showed that higher MVPA levels
among patients were associated with a lower risk of PTDM (hazard ratio (HR); 95% confidence
interval (95%CI) = 0.49; 0.25–0.96, p = 0.04), cardiovascular- (0.34; 0.15–0.77, p = 0.01), and all-cause
mortality (0.37; 0.24–0.58, p < 0.001) compared with No-MVPA patients, independently of age, sex,
and kidney function parameters. Associations of MVPA with cardiovascular and all-cause mortality
remained significant and materially unchanged following further adjustments made for transplant
characteristics, lifestyle factors, metabolic parameters, medication use, and creatinine excretion
(muscle mass). However, the association between MVPA and PTDM was no longer significant after
we adjusted for metabolic confounders and glucose levels. (4) Conclusion: Higher MVPA levels are
associated with long-term health outcomes in RTRs.
Keywords: physical activity; renal transplant recipients; transplantation; post-transplant diabetes
mellitus; cardiovascular mortality; mortality
1. Introduction
Renal transplantation is a more effective treatment strategy than chronic dialysis in patients with
end-stage renal disease [1]. However, post-transplant patients are at an increased risk of developing
cardiometabolic diseases that lead to high morbidity and mortality among renal transplant recipients
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(RTRs) [2,3]. The cardiovascular mortality rate is estimated to be 10 times higher for RTRs compared
with the general population [2]. Moreover, approximately 20% of RTRs develop post-transplant diabetes
mellitus (PTDM) [3]. This situation necessitates an investigation aimed at developing strategies for
improving the management of long-term health outcomes in RTRs.
Studies have consistently found that physical activity (PA) is a modifiable factor that contributes
to reducing the risk of cardiometabolic diseases and premature mortality within the general
population [4,5]. However, there is limited data on the impacts of PA on RTRs [6–10]. Studies
conducted on the benefits of PA have mostly focused on the intermediate outcomes of clinical trials
entailing exercise training programmes [6–8]. A few studies found that a low PA is significantly
associated with substantial weight gain and with risks of cardiovascular and all-cause mortality in
RTRs [11–14]. Moreover, it remains unclear whether the benefits of increased PA in relation to patients’
long-term outcomes are independent of their health and transplant characteristics (i.e., kidney function
and duration of pre-transplant dialysis), lifestyle factors, and use of medication [11–13].
Clinical guidelines for the general population recommend the performance of at least 150 min of
moderate-to-vigorous physical activity (MVPA) per week [15]. There are no specific clinical guidelines
or recommendations for RTRs. A recent position statement on exercise for solid organ transplant
recipients released in 2019 recommending that it is a key step toward raising awareness of the
importance of exercise training in the patients among transplant professionals [16]. The available data
show that the level of daily-life PA is lower for RTRs compared with individuals within the general
population [17–19]. It is unclear whether individuals within the general population as well as RTRs can
attain the recommended MVPA level by engaging in different domains of daily-life activities, such as
non-occupational and occupational activities. Results showed that occupational MVPA should not
be included within assessments of healthy daily-life PA and should not be deemed a substitute for
leisure time MVPA. Specifically, it is not known whether both non-occupational and occupational PA
can contribute to the improved health of RTRs [20–22].
Therefore, we aimed to investigate the association between daily-life MVPA and the risk of
developing long-term health outcomes, such as PTDM as well as cardiovascular and all-cause mortality
in RTRs sampled from a large prospective study. We also examined whether these associations were
independent of several variables, including age, sex, kidney function, transplant characteristics, lifestyle
factors, medication use, metabolic parameters, and anthropometric measures. Moreover, we assessed
the benefits of non-occupational MVPA as well as total daily-life MVPA, including occupational PA.
2. Methods
2.1. Study Population
This study was conducted in a large single-center prospective cohort of stable outpatient
RTR [23,24]. A total of 817 adult RTRs who met the study’s eligibility criteria, namely having a
functioning graft for at least 1 year and no history of alcohol and/or drug addiction, were invited to
participate in the study. Further exclusions were apparent systemic diseases, such as malignancies
or active infections. In total, 707 (86.5%) RTRs signed written informed consent. Baseline data were
collected between November 2008 and May 2011. We excluded 57 RTRs, whose PA questionnaires
were incomplete, from the analysis, leaving a total of 650 RTRs. Subsequently, 148 and 61 RTRs,
respectively, with a history of diabetes and cardiovascular diseases (CVDs) prior to undergoing
transplants, were excluded from the analyses of PA and the development of PTDM and cardiovascular
mortality. The study was conducted according to the Helsinki Declaration and was approved by the
UMCG’s review board (METc 2008/186).
2.2. Measurements at Baseline
All baseline measurements have been previously described in greater detail elsewhere [25].
Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2). A semiautomatic
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device (Dinamap®1846; Critikon, Tampa, FL, USA) was used to measure blood pressure in a half-sitting
position and the average of the final three readings of blood pressure was used. Information on
medication was derived from patient records. Daily caloric intake and alcohol consumption were
calculated from a validated Food Frequency questionnaire. Information on smoking was obtained by
a questionnaire. The serum creatinine-based Chronic Kidney Disease Epidemiology Collaboration
equation was used to calculate the estimated glomerular filtration rate (eGFR) [26]. Creatinine
excretion—a marker of muscle mass—was calculated from the 24-h urine collection as described
earlier [27].
2.3. Assessment of Physical Activity
The SQUASH is a validated questionnaire used to estimate habitual physical activities performed
during a normal week [28]. The SQUASH is pre-structured into four domains: commuting, leisure
time and sports, household, and occupational activities. Questions consisted of three main queries:
days per week, average time per day, and intensity. In this study, we used activities at the moderate
(4.0–6.5 MET) to vigorous (≥6.5 MET) level. Metabolic equivalent (MET) values were assigned to
activities according to Ainsworth’s Compendium of Physical Activities [29]. We used the combination
of leisure-time and commuting (non-occupational) moderate-to-vigorous physical activity (MVPA)
minutes per week (min/week) as a measure of PA in this study, since active commuting of high intensity
and longer duration is often replacing sports activities, like cycling. We did not include occupational
MVPA in the main analysis because of its health benefit is not clear in the general population [20–22,30].
In an additional analysis, we investigated the association between total MVPA, including occupational
MVPA, with clinical endpoints. Participants were subdivided into three categories based on their
levels of non-occupational MVPA. RTRs who did not engage in PA at a moderate-to-vigorous level
were deemed ‘inactive’ (no-MVPA), and the remaining participants (MVPA > 0) were divided into
two groups based on median values of non-occupational MVPA (less active, MVPA-1 and active,
MVPA-2). The MVPA min/week (median, interquartile range (IQR)) was used to define the MVPA
groups (MVPA-1 and MVPA-2): 5-197 (120, 60–150) and 200–1680 (360, 260–540).
2.4. Endpoints of the Study
Endpoints of interest in this study were post-transplant diabetes mellitus (PTDM), cardiovascular
and all-cause mortality. PTDM was defined according to the presence of at least one of the following
criteria: diabetes symptoms (e.g., polyuria, polydipsia, or unexplained weight loss) along with a
non-fasting plasma glucose concentration of ≥200 mg/dL (11.1 mmol/L); fasting plasma glucose
concentration (FPG) ≥ 126 mg/dL (7.0 mmol/L); start of antidiabetic medication; or HbA1c ≥ 6.5%
(48 mmol/L). This definition matched the diagnostic criteria for diabetes applied by the American
Diabetes Association, including HbA1c levels, as proposed by the expert panel constituted at the
international consensus meeting on PTDM [31,32]. Cardiovascular mortality and all-cause mortality
were monitored through continuous surveillance conducted within the outpatient program and
retrieved from patients’ files up to the end of September 2015. No participants were lost to follow-up.
2.5. Statistical Analysis
The patient characteristics are expressed as means with a standard deviation for normally
distributed variables or as medians with interquartile range (25th to 75th percentile) for non-normally
distributed variables and numbers with percentages in case of categorical data. The differences between
groups were tested using 1-way analysis of variance tests or Kruskal–Wallis tests for normally and
non-normally distributed continuous variables, respectively. The frequency distributions of categorical
variables were analyzed using the Pearson Chi-Square test.
We adopted MVPA as a continuous and categorical variable in a Cox regression analysis. First,
we tested associations of non-occupational MVPA, considered as a continuous variable, on clinical
endpoints. In this analysis, MVPA (measured in min/week) was log-transformed to obtain a normal
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distribution. Thereafter, multivariate Cox regression analyses were performed to examine whether
higher non-occupational MVPA is associated with lower risks of PTDM, cardiovascular mortality,
and all-cause mortality independently of potential confounders which are clinically known confounders
in the relating associations of physical activity with long-term outcomes [6,7,12–14,33]. In these analyses,
we first adjusted for age and sex (model 1) as well as kidney function parameters, including eGFR,
proteinuria, the time lapse between transplantation and the baseline measures, and primary renal
disease (model 2). We further adjusted model 1 for transplant characteristics (acute rejection, preemptive
transplantation, and living donor status) in model 3. Similarly, we adjusted model 1 for lifestyle factors,
such as smoking, alcohol consumption, and daily caloric intake (model 4); calcineurin inhibitors
and prednisolone used as immunosuppressive medication (model 5); systolic blood pressure, use of
antihypertensive drugs, high-density lipoprotein cholesterol (HDL), and triglycerides (model 6),
BMI and waist circumference (model 7), and 24-h creatinine excretion (model 8). With regard to
potential collinearity (model 7), we tested the correlation between BMI and waist circumference
(r = 0.84, p < 0.001 for men and r = 0.81, p < 0.001 for women). Then we performed Cox-regression
analyses using separate models adjusted for BMI and waist circumference separately (Supplementary
materials, Table S1. We found no differences relating to the confounding effects of total fat and fat
distribution. Finally, we included those variables in the same model. In addition, we adjusted model 1
for baseline hemoglobin A1C and fasting plasma glucose (model 9) relating to the association between
MVPA and PTDM. We also adjusted model 1 relating to the association between MVPA and PTDM for
diet quality (Model 10). We furthermore investigated whether diet quality might modify the association
of MVPA with development of PTDM by additional inclusion of a product-term of the continuous
variables of diet quality and MVPA in the concerned model, to assess potential interaction between the
two. Mediterranean diet score was used as diet quality and assessed with a 177-item validated food
frequency questionnaire which is described in greater detail elsewhere [33]. All models (1-10) include
up to 6 variables to fulfil the rule of thumb which allows 1 variable per 7–10 events. This is now fulfilled
for all analyses [34,35]. Hazard ratios were reported with 95% confidence intervals. Proportional
hazard assumptions were tested using the Schoenfield residuals method developed by Grambsch and
Therneau [36]. Penalized splines were constructed to visualize the association of non-occupational
MVPA with PTDM as well as cardiovascular and all-cause mortality independently of age and sex.
We performed additional analyses to explore the role of work within this population by investigating
the associations between total MVPA, including occupational MVPA, and non-occupational MVPA with
clinical endpoints for the RTRs who worked (n = 322, 49.5%). Occupational status was defined using
the answers for the questions related to occupational PA. If responders answered as not applicable,
we considered them as unemployed. Another subgroup analysis was performed to address changes
in these associations across age categories. The population was categorized as being over or under
55 years of age, based on the WHO guideline on the prevention of CVD [37]. Finally, to rule out
competing mortality risks associated with the occurrence of PTDM, we conducted competing risk
analyses following the procedures outlined by Fine and Gray [38].
A two-sided statistical significance was set at p < 0.05 for all tests. All statistical analyses were
performed using SPSS software V.22 (IBM Inc., Chicago, IL, USA,) R software V.3.2.2 (R Foundation for
Statistical Computing, Vienna, Austria), STATA version 13.0 (StataCorp LP, College Station, TX, USA)
and Graph Pad Prism 7 (Graph Pad Software Inc., La Jolla, CA, USA).
3. Results
3.1. Baseline Characteristics
A total of 650 RTRs (men: 56.3%, mean age: 51.8 ± 13.2 years old) were examined in this study.
Baseline measurements were taken 5.7 years (median value; interquartile range (IQR): 1.9–12.1 years)
post-transplantation. Of the total sample of RTRs, 37.8% (n = 246) did not perform daily MPVA at all
within any domain. The other RTRs spent a median of 200 min (IQR = 120–360 min per week) engaged
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in non-occupational MVPA. Table 1 shows the baseline characteristics of RTRs according to their
non-occupational MVPA levels. RTRs in the active groups (MVPA > 0) had lower values for BMI, waist
circumference, and systolic blood pressure and higher creatinine excretion values compared with the
values of the inactive group (no-MVPA). Moreover, higher alcohol consumption, lower concentrations
of triglycerides and HDL-C, haemoglobin A1C, and less proteinuria and diabetes at the baseline level
along with more ‘living donors’ were observed for the ‘active’ groups compared with the ‘inactive’
group. Table S2 presents the baseline characteristics of the RTRs according to the presence of clinical
endpoints. Figure S1 further shows levels of daily MVPA according to the participants’ ages and work
status. As expected, total MVPA values, including those for occupational MVPA, were significantly
higher in RTRs who were working (n = 322). However, when working status or age was considered,
the levels of non-occupational MVPA did not differ significantly.
Table 1. Characteristics of the study population, according to MVPA level.






(n = 203) p-Value
Age (years) 52.6 ± 12.8 54.1 ± 11.8 51.9 ± 13.4 51.6 ± 13.3 0.08
Male gender (%, n) 56.3 (366) 56.1 (138) 55.7 (112) 57.1 (116) 0.96
Current smoking (%, n) 12.3 (80) 15.3 (36) 12.4 (25) 9.5 (19) 0.20
Occupational status:
Employed * (%, n) 49.5 (322) 44.7 (110) 51.2 (103) 53.7 (109) 0.14
Alcohol use (g/day) 2.61 (0.1–11.1) 1.45 (0.1–9.7) 2.51 (0.1–9.7) 3.95 (0.1–14.1) 0.01
Total energy intake (kcal/d) 2174.9 ± 640.7 2114.7± 720.4 2247.5 ± 598.7 2173.2 ± 573.9 0.11
Non-occupational MVPA
(min/week) 90 (0–240) 0 120 (60–150) 360 (260–540) −
Anthropometric measures
Body mass index (kg/m2) 26.7 ± 4.84 27.9 ± 5.49 25.7 ± 4.26 26.1 ± 4.23 0.001
Waist circumference, men (cm) 101.1 ± 13.4 104.0 ± 13.7 98.9 ± 13.5 99.7 ± 12.4 0.01
Waist circumference, women (cm) 95.0 ± 15.8 99.7 ± 12.4 91.5 ± 14.6 93.1 ± 14.1 0.01
Creatinine excretion (mmol/24h) 11.7 ± 3.49 11.2 ± 3.80 11.8 ± 3.29 12.2 ± 3.23 0.01
Lipids and blood pressure
Total cholesterol (mmol/L) 5.14 ± 1.11 5.18 ± 1.18 5.17 ± 1.10 5.07 ± 1.02 0.48
Triglyceride (mmol/L) 1.68 (1.2–2.33) 1.85 (1.3–2.6) 1.67 (1.2–2.4) 1.59 (1.2–2.05) 0.001
HDL-C in men (mmol/L) 1.27 ± 0.41 1.23 ± 0.41 1.27 ± 0.36 1.32 ± 0.45 0.21
HDL-C in women (mmol/L) 1.56 ± 0.51 1.39 ± 0.43 1.62 ± 0.54 1.70 ± 0.53 0.001
Systolic blood pressure (mm Hg) 136.2 ± 17.3 138.3 ± 18.5 135.6 ± 16.7 134.2 ± 16.3 0.04
Diastolic blood pressure (mm Hg) 82.8 ± 10.9 83.1 ± 11.2 82.5 ± 11.3 82.6 ± 10.3 0.77
Cardiovascular medication use
Antihypertensive (%, n) 88 (572) 92.7 (228) 81.1 (163) 89.2 (181) 0.001
A2 antagonist (%, n) 14.8 (96) 15.4 (38) 12.9 (26) 15.8 (32) 0.68
ACE inhibitor (%, n) 32.2 (209) 32.1 (79) 30.3 (61) 34.0 (69) 0.74
RAAS blockers (%, n) 47.8 (311) 49.2 (121) 44.8 (90) 49.3 (100) 0.58
Beta-blockers (%, n) 63.2 (411) 63.4 (156) 62.2 (125) 64.0 (130) 0.93
Calcium channel blockers (%, n) 24.5 (159) 26.0 (64) 20.4 (41) 26.6 (54) 0.27
Diuretics (%, n) 40.0 (260) 52.0 (128) 27.4 (50) 37.9 (77) 0.001
Vitamin K antagonist (%, n) 11.4 (74) 13 (32) 10.4 (21) 10.3 (21) 0.60
mTOR inhibitor (%, n) 1.8 (12) 3.3 (8) 1 (2) 1 (2) 0.60
Anti-diabetic drugs (%, n) 14.8 (96) 18.7 (46) 14.4 (29) 10.3 (21) 0.045
Statin (%, n) 51.8 (337) 54.9 (135) 52.7 (106) 47.3 (96) 0.27
Glucose metabolism
Fasting plasma glucose (mmol/L) 5.67 ± 1.82 5.78 ± 192 5.76 ± 2.13 5.46 ± 1.28 0.13
Heamoglobin A1C (%) 5.94 ± 0.78 6.03 ± 0.77 5.94 ± 0.90 5.83 ± 0.65 0.021
Kidney function
eGFR (mL/min/1.73m2) 52.0 ± 20.2 49.9 ± 22.1 53.8 ± 18.7 52.9 ± 18.8 0.09
Albumin excretion (mg/24h) 267.3 ± 734.6 307.2 ± 777.5 175.1 ± 378.5 308.7 ± 917.5 0.11
Proteinuria (%, n) 21.5 (140) 28.0 (69) 16.9 (34) 18.2 (37) 0.01
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Table 1. Cont.






(n = 203) p-Value
Primary renal disease (%, n) 0.01
Glomerulosclerosis 28.8 (187) 30.1 (74) 28.4 (57) 27.6 (56)
Glomerulonephritis 7.7 (50) 5.7 (14) 8.0 (16) 9.9 (20)
Tubulointerstitial nephritis 11.8 (77) 9.8 (24) 12.9 (26) 13.3 (27)
Polycystic kidney disease 20.9 (136) 20.7 (51) 19.9 (40) 22.2 (45)
Renal hypodysplasia 3.5 (23) 4.1 (10) 3.0 (6) 3.4 (7)
Renavascular diseases 5.7 (37) 7.7 (19) 4.0 (8) 4.9 (10)
Diabetes mellitus 4.6 (30) 6.5 (16) 5.5 (11) 1.5 (3)
Others 16.9 (110) 15.4 (38) 18.4 (37) 17.2 (35)
Duration of dialysis before the
transplantation (months) 25 (8–48) 29 (11–51) 19 (4–49) 25 (9–43) 0.51
Transplant characteristics
Transplant vintage (months) 14.0 (2.0–39.5) 17.0 (2.0–41.0) 12.0 (2.0–44.8) 16.0 (0.5–41.0) 0.49
Cold ischemia time (h) 15.2 (2.8–21.1) 16.4 (3.6–22.0) 15.1 (2.6–21.3) 13.6 (2.5–20.5) 0.10
Living donor (%, n) 34.8 (226) 26.4 (65) 37.3 (75) 42.4 (86) 0.001
Pre-emptive transplant (%, n) 16.6 (108) 13.4 (33) 20.9 (42) 16.3 (33) 0.11
Acute rejection 27.2 (177) 27.2 (67) 27.9 (56) 26.6 (54) 0.96
Immunosuppressive medication
Calcineurin inhibitor (%, n) 58.3 (379) 59.8 (147) 59.2 (119) 55.7 (113) 0.52
Proliferation inhibitor (%, n) 82.6 (537) 80.1 (197) 84.1 (169) 84.2 (171) 0.62
Prednisolone dose (mg) 10.0 (7.5–10.0) 10.0 (7.5–10.0) 10.0 (7.5–10.0) 10.0 (7.5–10.0) 0.48
Data are presented as mean ± SD or median (interquartile range) and percentage (%, number). MVPA =
moderate-to-vigorous physical activity, HDL-C = high-density lipoprotein cholesterol, eGFR = estimated glomerular
filtration rate, A2 = angiotensin 2, ACE = angiotensin-converting-enzyme, RAAS = renin–angiotensin–aldosterone
system, mTOR = mammalian target of rapamycin. * the number of patients that do have employment.
3.2. Post-Transplant Diabetes Mellitus
A total of 50 RTRs (10%) had developed PTDM after a median follow-up period of 5.3 years
(4.1–6.0 years). The multivariable Cox proportional hazard models showed that the group with the
highest level of non-occupational MVPA was associated with a lower risk of PTDM (hazard ratio (HR);
95% CI = 0.49; 0.25–0.96, p = 0.04) compared with the no-MVPA group, independently of age, sex,
and kidney function parameters (model 1, Table 2). This association remained significant after we
made further adjustments for kidney function parameters, transplant characteristics, lifestyle factors,
Mediterranean diet score and 24-h creatinine excretion quantities (considered as a marker of muscle
mass) (models 2–4, 8, and 10). Following adjustments made for immunosuppressive medication
(model 5), metabolic parameters (model 6), anthropometric measures (model 7), and baseline glucose
levels (model 9), the highest level of MVPA was no longer associated with PTDM. However, when MVPA
was applied as a continuous variable in the Cox regression analysis, as opposed to using groups of
MVPA levels, a higher non-occupational MVPA was associated with a lower risk of PTDM independent
of all of the above-mentioned confounders apart from the adjustment of metabolic parameters and
glucose level.
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Table 2. Association of non-occupational MVPA with long-term health outcomes.
Physical
Activity
MVPA (cont.) No-MVPA(Ref) MVPA-1 MVPA-2
HR (95% CI) p HR (95% CI) p HR (95% CI) p
Post-transplant DM
No. of
events 50/502 23 14 13
Model 1 0.88 (0.79–0.97) 0.01 1.00 0.57 (0.29–1.10) 0.09 0.49 (0.25–0.96) 0.04
Model 2 0.88 (0.79–0.98) 0.02 1.00 0.61 (0.31–1.20) 0.15 0.49 (0.25–0.96) 0.04
Model 3 0.88 (0.79–0.98) 0.02 1.00 0.55 (0.28–1.07) 0.08 0.48 (0.24–0.95) 0.04
Model 4 0.87 (0.79–0.97) 0.01 1.00 0.57 (0.29–1.12) 0.10 0.46 (0.22–0.94) 0.03
Model 5 0.89 (0.80–0.99) 0.03 1.00 0.59 (0.30–1.26) 0.11 0.52 (0.26–1.03) 0.06
Model 6 0.91 (0.82–1.01) 0.09 1.00 0.70 (0.36–1.40) 0.31 0.60 (0.29–1.22) 0.16
Model 7 0.88 (0.79–0.99) 0.03 1.00 0.63 (0.31–1.25) 0.19 0.50 (0.25–1.03) 0.06
Model 8 0.87 (0.79–0.97) 0.01 1.00 0.55 (0.29–1.08) 0.08 0.47 (0.24–0.93) 0.03
Model 9 0.91 (0.82–1.01) 0.12 1.00 0.72 (0.36–1.41) 0.34 0.59 (0.30–1.19) 0.14
Model 10 0.87 (0.78–0.97) 0.01 1.00 0.58 (0.32–1.25) 0.11 0.44 (0.21–0.92) 0.03
Cardiovascular mortality
No. of
events 53/589 26 14 13
Model 1 0.84 (0.74–0.94) 0.01 1.00 0.45 (0.22–0.94) 0.03 0.34 (0.15–0.77) 0.01
Model 2 0.84 (0.75–0.95) 0.01 1.00 0.49 (0.23–1.02) 0.06 0.35 (0.16–0.80) 0.01
Model 3 0.86 (0.76–0.96) 0.01 1.00 0.51 (0.25–1.05) 0.07 0.40 (0.18–0.91) 0.03
Model 4 0.87 (0.77–0.98) 0.02 1.00 0.56 (0.26–1.21) 0.14 0.43 (0.19–0.94) 0.046
Model 5 0.84 (0.74–0.94) 0.001 1.00 0.45 (0.21–0.93) 0.03 0.36 (0.16–0.81) 0.01
Model 6 0.85 (0.76–0.96) 0.001 1.00 0.49 (0.23–1.02) 0.06 0.38 (0.17–0.86) 0.02
Model 7 0.85 (0.75–0.96) 0.01 1.00 0.51 (0.23–1.11) 0.09 0.40 (0.17–0.92) 0.03
Model 8 0.87 (0.77–0.98) 0.02 1.00 0.55 (0.26–1.16) 0.12 0.44 (0.19–0.99) 0.051
All-cause mortality
No. of
events 129/650 76 27 26
Model 1 0.84 (0.78–0.89) <0.001 1.00 0.39 (0.25–0.61) <0.001 0.37 (0.24–0.58) <0.001
Model 2 0.85 (0.79–0.91) <0.001 1.00 0.43 (0.27–0.67) <0.001 0.40 (0.26–0.63) <0.001
Model 3 0.85 (0.79–0.91) <0.001 1.00 0.41 (0.27–0.64) <0.001 0.41 (0.26–0.64) <0.001
Model 4 0.83 (0.77–0.89) <0.001 1.00 0.41 (0.21–0.64) <0.001 0.35 (0.22–0.58) <0.001
Model 5 0.83 (0.78–0.89) <0.001 1.00 0.39 (0.25–0.61) <0.001 0.37 (0.23–0.58) <0.001
Model 6 0.85 (0.79–0.91) <0.001 1.00 0.42 (0.27–0.66) <0.001 0.41 (0.26–0.65) <0.001
Model 7 0.84 (0.78–0.89) <0.001 1.00 0.40 (0.25–0.63) <0.001 0.37 (0.23–0.59) <0.001
Model 8 0.86 (0.80–0.92) <0.001 1.00 0.45 (0.29–0.70) <0.001 0.44 (0.28–0.69) <0.001
DM = Diabetes mellitus, MVPA = moderate-to-vigorous physical activity. Model 1: adjusted for age and sex.
Model 2: model 1 + adjustment for kidney function (eGFR, urinary protein excretion, time between transplantation
and baseline, and primary renal disease). Model 3: model 1 + adjustment for transplant characteristics (acute
rejection, pre-emptive transplantation, donor type). Model 4: model 1 + adjustment for lifestyle factors (smoking,
alcohol consumption, daily caloric intake). Model 5: model 1 + adjustment for immunosuppressive medication
(calcineurin inhibitors, prednisolonee). Model 6: model 1 + adjustment for lipids and blood pressure (systolic blood
pressure, use of antihypertensive drugs, triglycerides, HDL-C). Model 7: model 1 + adjustment for BMI and waist
circumference. Model 8: model 1 + adjustment for 24-h creatinine excretion. Model 9: model 1 + adjustment for
fasting plasma glucose and HbA1c. Model 10: model 1 + adjustment for Mediterranean diet score.
3.3. Cardiovascular and All-Cause Mortality
During the follow-up period, 129 (19.8%) patients died. Of these deaths, 53 (8.9%) were caused
by cardiovascular disease (CVD). In the multivariable Cox proportional hazard models, the highest
level of non-occupational MVPA was associated with a lower risk of cardiovascular mortality (HR;
95% CI = 0.34; 0.15–0.77, p = 0.01) compared with the no-MVPA group, independently of age, sex,
and kidney function parameters (model 1–2, Table 2). This association remained significant after further
adjustments were made for transplant characteristics, immunosuppressive medication, metabolic
parameters, and anthropometric measures (models 3, 5–7). However, the association was no longer
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significant after adjusting for lifestyle factors (model 4) and creatinine excretion (model 8). Moreover,
the association of MVPA with cardiovascular mortality was sustained independently of all of the
potential confounders when non-occupational MVPA was applied as a continuous variable in the Cox
regression (models 1–9, Table 2).
With regard to all-cause mortality, the group with the highest level of non-occupational MVPA was
associated with a lower risk of all-cause mortality (HR; 95% CI = 0.37; 0.24–0.58, p < 0.001) compared
with the no-MVPA group (model 1, Table 2). This association remained significant after we adjusted
for potential confounders (models 2–8). However, the association weakened after we adjusted for
transplant characteristics (model 3), metabolic parameters (model 6), and creatinine excretion (model
8). When log-transformed non-occupational MVPA was applied as a continuous variable in the Cox
regression analysis, the association was independent of all of the above-mentioned confounders, apart
from creatinine excretion (model 8), remaining materially unchanged.
To illustrate these associations further, age-and sex-adjusted penalized splines and the
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Figure 2. Probability of survival for PTDM (a), cardiovascular mortality (b), and all-cause mortality (c)
according to non-occupational MVPA level.
3.4. Additional Analyses
Additional analyses of the subgroup of working RTRs revealed that the inclusion of occupational PA
in the estimate of MVPA resulted in the attenuation of the HRs of all of the significant and non-significant
associations (Table 3). The association of non-occupational MVPA with cardiovascular and all-cause
mortality was stronger compared with that of total MVPA, which includes occupational MVPA.
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Table 3. Additional analysis on the associations of MVPA with long-term health outcomes in RTRs
who are working (n = 322).
Physical Activity MVPA (cont.) No-MVPA MVPA > 0
HRˆ (95% CI) p-value N * Reference N * HRˆˆ (95% CI) p-Value
Post-transplant DM
Non-occupational
PA 0.87 (0.74–1.03) 0.113 10 1.00 10 0.46 (0.18–1.13) 0.076
Total PA 0.91 (0.78–1.06) 0.212 8 1.00 12 0.48 (0.20–1.20) 0.056
Cardiovascular mortality
Non-occupational
PA 0.63 (0.48–0.83) 0.001 12 1.00 3 0.11 (0.11–0.42) 0.001
Total PA 0.75 (0.63–0.91) 0.003 9 1.00 6 0.23 (0.10–0.58) 0.051
All-cause mortality
Non-occupational
PA 0.76 (0.66–0.87) <0.01 25 1.00 11 0.21 (0.14–0.51) <0.01
Total PA 0.82 (0.74–0.92) 0.001 19 1.00 17 0.30 (0.18–0.58) <0.01
Total PA was the sum of non-occupational and occupational MVPA in min/week. DM = diabetes mellitus, MVPA =
moderate-to-vigorous physical activity, HR=hazard ratio, CVD = cardiovascular disease, N * = number of events.
ˆ Analyses were adjusted for age, gender, and kidney function parameters. ˆˆ Analyses were adjusted for age and
gender (kidney function parameters excluded in this analysis due to fulfill the rule of thumb).
Age-stratified analyses revealed that associations of MVPA with long-term health outcomes were
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Figure 3. Subgroup analysis for the associations of MVPA with long-term health outcomes over
age cat gories.
The results of the competing risk analyses showed that there was no strong influence of a competing
risk of all-cause m rtality n the associatio of MVPA ith PTDM. For instance, the competing HR
was 0.51 (0.30–0.92, p = 0.04) f r the highest MVPA with PTDM after adjusting for age a d sex.
By comparison, the HR was 0.49 (0.25–0.96, p = 0.04, model 1, Table 2) when competing risks
were discounted.
4. Discussion
We found that increased daily-life MVPA is associated with a reduced risk of PTDM, cardiovascular
mortality, and all-cause mortality in RTRs independently of age, sex, baseline kidney function
parameters, transplant characteristics, and other lifestyle habits. The association of MVPA with
PTDM was affected by the adjustments we made for baseline glucose levels and metabolic parameters,
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but it did not seem to be affected by other potential confounders, notably anthropometric and
immunosuppressive medication. The associations of MVPA with cardiovascular and all-cause
mortality were not substantially affected by adjustments made for the above-mentioned confounders.
These results confirm the importance of PA in the long-term healthcare management of RTRs.
Previous studies have found that PTDM is highly prevalent in RTRs [3,39]. However, data on
lifestyle interventions for improving glucose tolerance or observational data on the association of
increased PA with incidences of PTDM are lacking [13,40]. An intervention study showed that lifestyle
modifications, including the incorporation of exercise training, improved 2-h postprandial glucose
levels in RTRs who were glucose intolerant [40]. One observational study found that higher levels
of PA are associated with a lower risk of glucose intolerance in RTRs [13]. However, this study
entailed a cross-sectional design and did not test whether this association of PA is independent of other
potential confounders. In our longitudinal study, the association of MVPA with PTDM was found to
be independent of age, sex, baseline kidney function parameters, transplant characteristics, and other
lifestyle factors, such as smoking, alcohol use, and diet (daily caloric intake and Mediterranean diet
score). However, the association was affected by adjustments made for immunosuppressive medication,
anthropometric measures (BMI and waist circumference), baseline glucose levels, and metabolic
parameters. It is widely accepted that obesity is associated with the development of diabetes within the
general population [41]. The use of immunosuppressive medications play a role in the development
of PTDM through a pathway of stimulation of gluconeogenesis affecting increased blood glucose
which can leads to insulin resistance in combination with other mechanisms [39]. However, when we
applied log-transformed continuous MVPA, significant associations were observed after we adjusted
for immunosuppressive medication and anthropometric measures, indicating that statistical power
issues may also play a role. Thus, further large-scale studies of a longer duration should be conducted
to explore whether or not MVPA is associated with PTDM independently of immunosuppressive
medication and obesity. Furthermore, diet is an important factor in the development of diabetes.
A previous analysis by Osté et al. for our study population showed that Mediterranean style diet
predicts the development of PTDM [33]. We found that the association between MVPA and PTDM
became slightly stronger when adjusted for Mediterranean diet score indicating the importance of diet,
but there was no effect modification by diet quality (P-interaction = 0.147).
A previous study, investigating another sample of RTRs, found that a lower PA is strongly
associated with an increased risk of cardiovascular and all-cause mortality [14]. In their Cox regression
analyses, these authors found that the association was independent of potential confounders, including
the history of CVD, muscle mass, and Framingham CVD risk score factors. However, they did not
adjust for some clinical variables, such as kidney function and transplant characteristics (e.g., transplant
vintage and donor type). Our study supports an independent association of PA with the risk of
cardiovascular and all-cause mortality. Many studies have pointed to the benefit of PA within the
general population in preventing premature mortality [4,5]. One of the mechanisms proposed to explain
the effects of increased PA entails the improvement of all organ systems, especially the cardiovascular
system. Specifically in RTRs, improved cardiovascular function is associated with improvements
in kidney function. Increased physical activity can support perfusion and oxygen delivery in the
kidneys. Studies have shown that higher levels of daily-life PA are associated with a lower risk of renal
function decline within the general population and in patients with chronic kidney disease [42–44].
Consequently, increased PA, by improving kidney function, may be of benefit for long-term graft
survival. This effect may also be due to improvements in metabolic dysfunctions, such as insulin
resistance, impaired glucose tolerance, dyslipidemia, and hypertension, all of which are related to
(central) adiposity [45–47]. Furthermore, a number of studies on diet analysed in-depth the effect of
dietary factors on the same outcomes such as PTDM, renal function decline and mortality [23–25,33,48].
They suggest that lifestyle is very important for RTR, however, it should be noted that MVPA in daily
life has not gotten that much attention. Taken together, these findings suggest that the improvement of
daily-life MVPA needs to be evaluated as a therapy for improving patients’ long-term survival.
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Within this RTR population, MVPA levels were lower than those within the general population.
In our study, 38% of RTRs were inactive (no-MVPA), whereas in the Lifelines cohort, a population-based
study for which the same questionnaire (SQUASH) and comparable data processing methods were
used, the prevalence of inactivity (no-MVPA) was 10% (n = 125,402, 40.5% males, median age of
45) [30,49]. Even in different age groups and gender, it was lower, ranging between 7.5% (n = 42,661,
40% of males, median age of 40) and 12.5% (n = 34,506, 45.6% of males, median age of 56) in the Lifelines.
Lower PA levels among RTRs may be attributed to lower muscle mass (a structural abnormality)
and muscle weakness (a functional abnormality) [6]. Our descriptive analysis indicated that inactive
RTRs had a lower 24-h creatinine excretion value (a marker of muscle mass) compared with that of
active RTRs. We also found that the duration of pre-transplantation dialysis was longer in inactive
RTRs, although not significantly so. Studies concluded that low muscle mass can be caused by low PA
levels [6,7,9]. This conclusion is in line with our findings, indicating that the association was slightly
attenuated after we adjusted for renal factors and muscle mass but that the effect of PA remained
evident. Actually a shorter time on dialysis would thus also help post-transplant health because
studies showed that the level of PA declines in patients with end-stage kidney diseases and it increases
after transplantation [7]. Finally, both recovery of activity after transplantation, as well as prevention
of inactivity and loss of muscle mass in people with longstanding kidney disease is important for
long-term health after transplantation.
A growing body of evidence is showing that occupational MVPA may have no clear benefit on
health in the general population [20–22,30,49]. This was tested in our study including a specific patient
population, the RTR. Even in the case of RTR, where being at work may be indicative of relatively
good health, individuals who were much more active in terms of their occupational MVPA may not
obtain any additional benefits for health. A clear mechanism that prevents occupational PA from
generating health benefits is missing. There is always the possibility of residual confounding by factors
such as sex, socioeconomic status, work-related stress, and body weight in the association between
occupational PA and health outcomes [20,22,30,49]. Studies attempted to explore the possibility of
residual confounding, but also found no clear association of occupational MVPA and health outcomes.
Thus, we suggest that it is important to be aware that occupational MVPA should not be considered as
a substitute for leisure time MVPA in RTR.
The potential benefit of PA seems to be more pronounced in older adults, a phenomenon that
was described before in the general population [50]. In the general population, studies concluded
that the benefit of PA can be gained more easily when there is more room for improvement, like as
in older people. However, it might also be that its effects will be potentially outweighed by other,
more important clinical factors (e.g., comorbidities and medication use). Therefore, we attempted to
test the effect of physical activity in specific groups such as in RTR in two age groups. We found that a
higher MVPA is strongly associated with the development of long-term outcomes such as PTDM and
cardiovascular mortality in younger and older adults, but is especially stronger in older adults. Thus,
older RTR who are able to remain active despite their longstanding condition are likely to remain
relatively healthy.
The strengths of this study include its prospective design, long duration, and complete follow-up.
Another strength is we included stable RTRs after transplantation and studied relevant clinical outcomes.
Nevertheless, there are some limitations to our study. The observational nature of the study precludes
us from drawing conclusions regarding causality. A limitation of this study was its use of self-reporting,
which is subject to recall bias, for the PA assessment. However, the SQUASH questionnaire has been
validated within general as well as specific populations, such as patients who have undergone total
hip arthroplasty and those with ankylosing spondylitis [28,51,52]. Furthermore, PA was assessed at a
single point in time. However, in RTR, after 1-year of transplantation, PA is increased by 30% and
remained materially unchanged the next 5-years [18]. In this study, we included RTR > 1 year graft
functioning with a median of 5.7 years post-transplantation. Another limitation is that we could not
fully control for the history of all cardiometabolic diseases in the association of MVPA with all-cause
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mortality. Patients with a history of diabetes or CVD before the transplantation were excluded from
the analyses on the association between MVPA and PTDM or CV mortality. However, cardiometabolic
diseases might be more prevalent in ‘No-MVPA’ group after transplantation as well. A limitation is
that we could not have data on functional evaluations, like e.g., a 6 min walking test, which could have
provided important information on cardiovascular efficiency. Finally, single-center nature of study,
which mainly consisted of white people is unclear whether our findings can be extrapolated to other
populations. It would be relevant to repeat our study in other patient populations.
5. Conclusions
Higher daily-life MVPA is associated with a reduced risk of PTDM as well as cardiovascular
and all-cause mortality in RTRs, suggesting that PA has a positive influence on the long-term health
management of RTRs. The associations of MVPA with cardiovascular and all-cause mortality were not
substantially affected by adjustments made for potential confounders, such as age, sex, baseline kidney
function parameters, transplant characteristics, lifestyle habits, metabolic parameters, anthropometric
measures, and immunosuppressive medication. The association of MVPA with PTDM was affected by
adjustments of metabolic parameters and glucose levels. The potentially beneficial effects of daily-life
PA apply to non-occupational activities at the moderate-to-vigorous level (e.g., commuting, leisure
activities, or sport). By contrast, a higher level of occupational MVPA is not directly associated with
the development of long-term outcomes. The associations of non-occupational MVPA and the risk
of PTDM and cardiovascular mortality were also stronger in older adults. Finally, we suggest that
because of the long-term importance of PA, it should be embedded in the healthcare management of
RTRs. Furthermore, large scale interventional studies are needed to test the ab initio effect of physical
activity after transplantation on the development of post-transplant diabetes mellitus.
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